Name: RMC-6291 Cat#: EX-A7663

Chemical Structure of RMC-6291:



Chemical Name	1-(4-(dimethylamino)-4-methylpent-2-ynoyl)-N-((2S)-1-(((22S,63S,4S)-11-ethyl-12-(2-((S)-1-methoxyethyl)pyridin-3-yl)-10,10-dimethyl-5,7-dioxo-61,62,63,64,65,66-hexahydro-11H-8-oxa-2(4,2)-morpholina-1(5,3)-indola-6(1,3)-pyridazinacycloundecaphane-4-yl)amino)-3-methyl-1-oxobutan-2-yl)-4-fluoro-N-methylpiperidine-4-carboxamide

Molecular Weight	1012.28	Storage	3 years -20°C powder 6 months -80°C in solvent Away from light
Formula	C55H78FN9O8		
CAS No.	2641998-63-0	Synonyms	RMC 6291; RMC6291

Solubility (25°C) *	In vitro	DMSO	Soluble
		Ethanol	N/A
		Water	N/A
	In vivo (should be freshly prepared each time)		

* <1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual

solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions:

Mass / Volume / Concentration	1 mg	5 mg	10 mg
1 mM	0.9879 mL	4.9393 mL	9.8786 mL
5 mM	0.1976 mL	0.9879 mL	1.9757 mL
10 mM	0.0988 mL	0.4939 mL	0.9879 mL

*The above data is based on the product molecular weight 1012.28.

Biological Activities:

Description	RMC-6291 is an orally active and covalent inhibitor of $KRAS^{G12C}$(ON). RMC-6291 forms a tri-complex within tumor cells between $KRAS^{G12C}$(ON) and cyclophilin A (CypA). RMC-6291 elicits deep and durable suppression on RAS pathway activity in $KRAS^{G12C}$ tumor models[1].

References	[1]. Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS." Science (New York, N.Y.) vol. 381,6659 (2023): 794-799. [2]. Nichols R J, et al. RMC-6291, a next-generation tri-complex KRASG12C (ON) inhibitor, outperforms KRASG12C (OFF) inhibitors in preclinical models of KRASG12C cancers[J]. Cancer Research, 2022, 82(12_Supplement): 3595-3595.